215 related articles for article (PubMed ID: 34319626)
1. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
Zhao Q; Guo N; Chen J; Parks D; Tian Z
J Clin Pharm Ther; 2022 Feb; 47(2):146-156. PubMed ID: 34319626
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
[No Abstract] [Full Text] [Related]
3. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ
Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
[TBL] [Abstract][Full Text] [Related]
4. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
Petrovič M; Locatelli I
Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
[No Abstract] [Full Text] [Related]
5. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
[TBL] [Abstract][Full Text] [Related]
6. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis.
Fu W; He W; Li Y; Chen Y; Liang J; Lei H; Fu L; Chen Y; Ren N; Jiang Q; Shen Y; Ma R; Wang T; Wang X; Zhang N; Xiao D; Liu C
Drug Deliv; 2021 Dec; 28(1):1007-1019. PubMed ID: 34060401
[No Abstract] [Full Text] [Related]
9. Role of ambrisentan in the management of pulmonary hypertension.
Hrometz SL; Shields KM
Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
[TBL] [Abstract][Full Text] [Related]
10. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
McGoon MD; Frost AE; Oudiz RJ; Badesch DB; Galie N; Olschewski H; McLaughlin VV; Gerber MJ; Dufton C; Despain DJ; Rubin LJ
Chest; 2009 Jan; 135(1):122-129. PubMed ID: 18812445
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis.
Duo-Ji MM; Long ZW
Int J Cardiol; 2017 May; 234():90-98. PubMed ID: 28233631
[TBL] [Abstract][Full Text] [Related]
12. Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study.
Gong SG; Wang L; Pudasaini B; Yuan P; Jiang R; Zhao QH; He J; Zhang R; Wu WH; Liu JM; Zhou CC
Can Respir J; 2018; 2018():9836820. PubMed ID: 29849836
[TBL] [Abstract][Full Text] [Related]
13. [Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
Macías Saint-Gerons D; de la Fuente Honrubia C; Montero Corominas D; Catalá-López F
Med Clin (Barc); 2014 Apr; 142(8):333-42. PubMed ID: 23540381
[TBL] [Abstract][Full Text] [Related]
14. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Dranitsaris G; Mehta S
Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
[TBL] [Abstract][Full Text] [Related]
15. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
[TBL] [Abstract][Full Text] [Related]
16. Ambrisentan: a review of its use in pulmonary arterial hypertension.
Rivera-Lebron BN; Risbano MG
Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
[TBL] [Abstract][Full Text] [Related]
17. Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report).
Takahashi T; Hayata S; Kobayashi A; Onaka Y; Ebihara T; Hara T
Clin Drug Investig; 2018 Mar; 38(3):219-229. PubMed ID: 29282676
[TBL] [Abstract][Full Text] [Related]
18. Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study.
Lau E; Kotlyar E; Makanji Y; Yu DY; Tan JY; Casorso J; Kouhkamari MH; Lim S; Wu DB; Bloomfield P
J Med Econ; 2024; 27(1):596-604. PubMed ID: 38488130
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of pulmonary arterial hypertension drugs in treatment-naive patients: a network meta-analysis.
Petrovič M; Locatelli I
J Comp Eff Res; 2020 Jan; 9(1):7-22. PubMed ID: 31845591
[No Abstract] [Full Text] [Related]
20. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.
Takatsuki S; Rosenzweig EB; Zuckerman W; Brady D; Calderbank M; Ivy DD
Pediatr Pulmonol; 2013 Jan; 48(1):27-34. PubMed ID: 22511577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
